BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
Titel:
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
Auteur:
Lui, Goldie Y.L. Shaw, Reid Schaub, Franz X. Stork, Isabella N. Gurley, Kay E. Bridgwater, Caroline Diaz, Robert L. Rosati, Rachele Swan, Hallie A. Ince, Tan A. Harding, Thomas C. Gadi, Vijayakrishna K. Goff, Barbara A. Kemp, Christopher J. Swisher, Elizabeth M. Grandori, Carla